Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genta Genasense "Not Approvable"; Firm Blames Composite Endpoint

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO Warrell tells "The Pink Sheet" DAILY that progression-free survival has no clinical value in the chronic lymphocytic leukemia setting.

You may also be interested in...



FDA Wants Another Trial Of Genta’s Genasense For CLL

FDA’s complete response letter requesting another trial concludes the agency’s review of an amended NDA submitted after an unsuccessful appeal of a “not approvable” letter.

FDA Wants Another Trial Of Genta’s Genasense For CLL

FDA’s complete response letter requesting another trial concludes the agency’s review of an amended NDA submitted after an unsuccessful appeal of a “not approvable” letter.

FDA Clears Path For Genta’s Genasense In Chronic Lymphocytic Leukemia

Agency acknowledges complete response as an appropriate primary endpoint for study; needs confirmatory evidence.

Related Content

Topics

UsernamePublicRestriction

Register

PS063552

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel